An express method was developed for production of a radiopharmaceutical (RP
) for intravenous injection based on thallium-199 chloride. The procedure i
nvolves distillation of thallium in the form of chloride in a hermetically
sealed quartz installation in a flow of hydrogen chloride, followed by cond
ensation of the nuclides in traps filled with water. After adding NaCl to o
btain a physiological solution and removing HCl by evaporation, the residue
is dissolved in water and sterilized. The total duration of the procedure
is about 2 h.